Lantern Pharma Inc. said in a filing with the SEC that it has formally established Open-Medicine AI as a separate company to commercialize and expand its multi-agentic AI co-scientist platform, previously operated as withZeta.ai.
According to the filing, Lantern Pharma has executed commercial licensing agreements with Open-Medicine AI, granting the new entity access to Lantern's withZeta.ai-related models, data, algorithms, and other assets and personnel. The agreements have received Lantern Pharma Board approval and are consistent with the framework outlined in the company's May 2026 registered direct financing, the filing said.
The filing states that Open-Medicine AI will continue to advance the multi-agentic architecture first proven in oncology and rare cancer research while expanding into additional disease areas. Lantern established and staffed an AI Center of Excellence in Bengaluru, India, in the first quarter of 2026, which will work alongside the existing Dallas team on multi-agent systems, computational biology modeling, knowledge engineering, and scientific curation, according to the filing.
Per the filing, the global market for AI-enabled drug discovery and development tools is projected to exceed $10 billion by 2030, with oncology representing the largest therapeutic segment and compound annual growth rates above 30 percent. The filing notes that major general-purpose AI companies, including Anthropic and OpenAI, have signaled or begun developing platforms aimed at scientific discovery and drug development.
The filing describes Open-Medicine AI's platform as combining specialized agent roles, recursive investigation modes, living knowledge graphs, and production tools including blood-brain barrier prediction, multi-omic analytics via ZetaOmics, and generative chemistry capabilities. Panna Sharma, President and CEO of Lantern Pharma and Founder of Open-Medicine AI, said in the filing that the new corporate structure and commercial licenses are intended to help scale the platform across oncology and into additional complex disease areas, and to pursue dedicated funding and a valuation path distinct from Lantern's clinical activity.
$LTRNLantern PharmaPrice$2.89 ▼1.37%Net sentiment—Mentions · 30d—Avg volume34,264View on the dashboardFinazon · prior-day close · Jul 17, 2026